| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Antitumour metal compounds: more than theme and variations.
|
Dalton Trans
|
2007
|
1.64
|
|
2
|
Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.
|
Chem Rev
|
2006
|
1.55
|
|
3
|
Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.
|
J Med Chem
|
2009
|
1.51
|
|
4
|
Anticancer activity of metal complexes: involvement of redox processes.
|
Antioxid Redox Signal
|
2011
|
1.32
|
|
5
|
The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways.
|
J Biol Inorg Chem
|
2008
|
1.11
|
|
6
|
Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP.
|
Dalton Trans
|
2006
|
1.10
|
|
7
|
Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic concentrations.
|
Arch Toxicol
|
2011
|
1.10
|
|
8
|
An internal fluorescent probe based on anthracene to evaluate cation-anion interactions in imidazolium salts.
|
Chemistry
|
2010
|
1.07
|
|
9
|
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes.
|
J Inorg Biochem
|
2010
|
1.04
|
|
10
|
Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells.
|
J Anal At Spectrom
|
2009
|
1.01
|
|
11
|
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential.
|
J Med Chem
|
2005
|
0.97
|
|
12
|
Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
|
J Med Chem
|
2008
|
0.95
|
|
13
|
A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core.
|
Chemistry
|
2011
|
0.92
|
|
14
|
Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
|
J Med Chem
|
2007
|
0.92
|
|
15
|
Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds.
|
J Biol Inorg Chem
|
2012
|
0.92
|
|
16
|
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
|
Anticancer Drugs
|
2009
|
0.91
|
|
17
|
Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?
|
Inorg Chem
|
2010
|
0.90
|
|
18
|
CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.
|
J Inorg Biochem
|
2007
|
0.89
|
|
19
|
Phosphite-derivatized ruthenium-carbohydrate complexes in the catalytic hydration of nitriles. short communication.
|
Chem Biodivers
|
2008
|
0.88
|
|
20
|
A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?
|
ChemMedChem
|
2007
|
0.88
|
|
21
|
Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin.
|
Electrophoresis
|
2004
|
0.87
|
|
22
|
Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma.
|
Electrophoresis
|
2008
|
0.87
|
|
23
|
Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands.
|
J Inorg Biochem
|
2012
|
0.87
|
|
24
|
The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE-MS techniques.
|
Electrophoresis
|
2009
|
0.86
|
|
25
|
Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
|
Dalton Trans
|
2010
|
0.86
|
|
26
|
Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
|
Dalton Trans
|
2007
|
0.86
|
|
27
|
High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides.
|
Inorg Chem
|
2008
|
0.86
|
|
28
|
Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds.
|
Inorg Chem
|
2012
|
0.85
|
|
29
|
Extravasation of Pt-based chemotherapeutics - bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS).
|
Metallomics
|
2015
|
0.85
|
|
30
|
Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds.
|
J Inorg Biochem
|
2007
|
0.85
|
|
31
|
The hydration of chloroacetonitriles catalyzed by mono- and dinuclear Ru(II)- and Os(II)-arene complexes.
|
Chem Biodivers
|
2008
|
0.85
|
|
32
|
Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
|
Chem Biodivers
|
2008
|
0.85
|
|
33
|
Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
|
J Biol Inorg Chem
|
2012
|
0.84
|
|
34
|
Anticancer activity of methyl-substituted oxaliplatin analogs.
|
Mol Pharmacol
|
2012
|
0.84
|
|
35
|
Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
|
Electrophoresis
|
2006
|
0.83
|
|
36
|
The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes.
|
Electrophoresis
|
2010
|
0.83
|
|
37
|
A new target for gold(I) compounds: glutathione-S-transferase inhibition by auranofin.
|
J Inorg Biochem
|
2012
|
0.83
|
|
38
|
Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)].
|
J Inorg Biochem
|
2008
|
0.82
|
|
39
|
Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.
|
J Biol Inorg Chem
|
2010
|
0.82
|
|
40
|
Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands.
|
Mol Pharmacol
|
2006
|
0.82
|
|
41
|
Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis.
|
J Chromatogr A
|
2007
|
0.82
|
|
42
|
Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
|
Chemistry
|
2009
|
0.81
|
|
43
|
DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media.
|
Biochem Pharmacol
|
2008
|
0.81
|
|
44
|
Tumour-inhibiting platinum(II) complexes with aminoalcohol ligands: biologically important transformations studied by micellar electrokinetic chromatography, nuclear magnetic resonance spectroscopy and mass spectrometry.
|
Analyst
|
2005
|
0.81
|
|
45
|
In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands.
|
Chemistry
|
2008
|
0.81
|
|
46
|
Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5'-monophosphate O6-N7 chelation.
|
Chembiochem
|
2004
|
0.81
|
|
47
|
From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
|
J Inorg Biochem
|
2010
|
0.80
|
|
48
|
Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice.
|
Metallomics
|
2014
|
0.80
|
|
49
|
Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
|
Anal Biochem
|
2005
|
0.80
|
|
50
|
{(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo.
|
J Med Chem
|
2010
|
0.80
|
|
51
|
Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICP-MS.
|
Electrophoresis
|
2009
|
0.80
|
|
52
|
Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method.
|
J Sep Sci
|
2005
|
0.79
|
|
53
|
3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands.
|
Dalton Trans
|
2013
|
0.79
|
|
54
|
Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules.
|
Chem Commun (Camb)
|
2011
|
0.79
|
|
55
|
Physicochemical Studies and Anticancer Potency of Ruthenium η-p-Cymene Complexes Containing Antibacterial Quinolones.
|
Organometallics
|
2011
|
0.79
|
|
56
|
Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins.
|
J Inorg Biochem
|
2011
|
0.79
|
|
57
|
DNA interactions of pH-sensitive, antitumor bis(aminoalcohol)dichloroplatinum(II) complexes.
|
Biochemistry
|
2006
|
0.79
|
|
58
|
Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes.
|
J Biol Inorg Chem
|
2013
|
0.79
|
|
59
|
Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
|
Chemistry
|
2013
|
0.78
|
|
60
|
DNA damaging properties of single walled carbon nanotubes in human colon carcinoma cells.
|
Nanotoxicology
|
2011
|
0.78
|
|
61
|
Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTA complexes and their anticancer activity.
|
Dalton Trans
|
2015
|
0.78
|
|
62
|
Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder.
|
Chem Commun (Camb)
|
2012
|
0.78
|
|
63
|
Fragmentation methods on the balance: unambiguous top-down mass spectrometric characterization of oxaliplatin-ubiquitin binding sites.
|
Anal Bioanal Chem
|
2011
|
0.78
|
|
64
|
Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications.
|
Electrophoresis
|
2012
|
0.78
|
|
65
|
Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity.
|
Chem Commun (Camb)
|
2013
|
0.77
|
|
66
|
LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma.
|
Metallomics
|
2011
|
0.77
|
|
67
|
Synthesis, cytotoxicity, and COMPARE analysis of ferrocene and [3]ferrocenophane tetrasubstituted olefin derivatives against human cancer cells.
|
ChemMedChem
|
2010
|
0.77
|
|
68
|
Organometallic ruthenium and osmium compounds of pyridin-2- and -4-ones as potential anticancer agents.
|
Chem Biodivers
|
2012
|
0.77
|
|
69
|
Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands.
|
J Med Chem
|
2012
|
0.77
|
|
70
|
Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent.
|
Dalton Trans
|
2014
|
0.77
|
|
71
|
Half-sandwich ruthenium(II) biotin conjugates as biological vectors to cancer cells.
|
Chemistry
|
2015
|
0.77
|
|
72
|
Capillary zone electrophoresis and capillary zone electrophoresis-electrospray ionization mass spectrometry studies on the behavior of anticancer cis- and trans-[dihalidobis(2-propanone oxime)platinum(II)] complexes in aqueous solutions.
|
J Chromatogr A
|
2012
|
0.76
|
|
73
|
Interactions of the carrier ligands of antidiabetic metal complexes with human serum albumin: a combined spectroscopic and separation approach with molecular modeling studies.
|
Bioorg Med Chem
|
2011
|
0.76
|
|
74
|
A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2'-deoxyguanosine 5'-monophosphate (dGMP).
|
Anal Bioanal Chem
|
2013
|
0.76
|
|
75
|
Solution equilibria of anticancer ruthenium(II)-(η(6)-p-cymene)-hydroxy(thio)pyr(id)one complexes: impact of sulfur vs. oxygen donor systems on the speciation and bioactivity.
|
J Inorg Biochem
|
2013
|
0.76
|
|
76
|
Physicochemical studies on the copper(II) binding by glycated collagen telopeptides.
|
Org Biomol Chem
|
2015
|
0.76
|
|
77
|
Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.
|
Electrophoresis
|
2007
|
0.75
|
|
78
|
5-Hydr-oxy-2-methyl-4H-pyran-4-one.
|
Acta Crystallogr Sect E Struct Rep Online
|
2009
|
0.75
|
|
79
|
Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development.
|
Chemistry
|
2013
|
0.75
|
|
80
|
Efficiently detecting metallodrug-protein adducts: ion trap versus time-of-flight mass analyzers.
|
ChemMedChem
|
2014
|
0.75
|
|
81
|
Nitrile-functionalized pyrrolidinium ionic liquids as solvents for cross-coupling reactions involving in situ generated nanoparticle catalyst reservoirs.
|
Phys Chem Chem Phys
|
2009
|
0.75
|
|
82
|
The metalation of hen egg white lysozyme impacts protein stability as shown by ion mobility mass spectrometry, differential scanning calorimetry, and X-ray crystallography.
|
Chem Commun (Camb)
|
2017
|
0.75
|
|
83
|
Synthesis and Evaluation of In Vitro Biological Properties of Ferrocenyl Side-Chain-Decorated Paclitaxel.
|
ChemMedChem
|
2017
|
0.75
|
|
84
|
Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.
|
Anal Bioanal Chem
|
2012
|
0.75
|
|
85
|
A one step/one pot synthesis of N,N-bis(phosphonomethyl)amino acids and their effects on adipogenic and osteogenic differentiation of human mesenchymal stem cells.
|
Bioorg Med Chem
|
2009
|
0.75
|
|
86
|
Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand.
|
J Biol Inorg Chem
|
2010
|
0.75
|